News & Events about Celcuity Inc.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors...
MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses. The...
High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported for patients who were treatment naïve in the advanced settingMINNEAPOLIS, MN...
MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast...
MINNEAPOLIS, MN/ ACCESSWIRE / November 3, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that it will release its financial results for the third quarter 2022 after the stock...